These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

401 related articles for article (PubMed ID: 17644123)

  • 1. Assessing and treating patients with increasing prostate specific antigen following radical prostatectomy.
    Sandler HM; Eisenberger MA
    J Urol; 2007 Sep; 178(3 Pt 2):S20-4. PubMed ID: 17644123
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Natural history of biochemical recurrence after radical prostatectomy: risk assessment for secondary therapy.
    Simmons MN; Stephenson AJ; Klein EA
    Eur Urol; 2007 May; 51(5):1175-84. PubMed ID: 17240528
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation and management of prostate-specific antigen recurrence after radical prostatectomy for localized prostate cancer.
    Naito S
    Jpn J Clin Oncol; 2005 Jul; 35(7):365-74. PubMed ID: 15976063
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PSA relapse prostate cancer: the importance of tailored therapy.
    Aranha O; Vaishampayan U
    Urol Oncol; 2004; 22(1):62-9. PubMed ID: 14969807
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Radical prostatectomy for clinically localized, high risk prostate cancer: critical analysis of risk assessment methods.
    Yossepowitch O; Eggener SE; Bianco FJ; Carver BS; Serio A; Scardino PT; Eastham JA
    J Urol; 2007 Aug; 178(2):493-9; discussion 499. PubMed ID: 17561152
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Detectable prostate specific antigen between 60 and 120 days following radical prostatectomy for prostate cancer: natural history and prognostic significance.
    Sengupta S; Christensen CM; Zincke H; Slezak JM; Leibovich BC; Bergstralh EJ; Myers RP; Blute ML
    J Urol; 2006 Aug; 176(2):559-63. PubMed ID: 16813889
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Variation in the definition of biochemical recurrence in patients treated for localized prostate cancer: the American Urological Association Prostate Guidelines for Localized Prostate Cancer Update Panel report and recommendations for a standard in the reporting of surgical outcomes.
    Cookson MS; Aus G; Burnett AL; Canby-Hagino ED; D'Amico AV; Dmochowski RR; Eton DT; Forman JD; Goldenberg SL; Hernandez J; Higano CS; Kraus SR; Moul JW; Tangen C; Thrasher JB; Thompson I
    J Urol; 2007 Feb; 177(2):540-5. PubMed ID: 17222629
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Locally recurrent prostate cancer after initial radiation therapy: a comparison of salvage radical prostatectomy versus cryotherapy.
    Pisters LL; Leibovici D; Blute M; Zincke H; Sebo TJ; Slezak JM; Izawa J; Ward JF; Scott SM; Madsen L; Spiess PE; Leibovich BC
    J Urol; 2009 Aug; 182(2):517-25; discussion 525-7. PubMed ID: 19524984
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The value of radiotherapy in treating recurrent prostate cancer after radical prostatectomy.
    Stephenson AJ; Slawin KM
    Nat Clin Pract Urol; 2004 Dec; 1(2):90-6. PubMed ID: 16474521
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prostate specific antigen recurrence after definitive therapy.
    Freedland SJ; Moul JW
    J Urol; 2007 Jun; 177(6):1985-91. PubMed ID: 17509277
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Oncologic outcome and patterns of recurrence after salvage radical prostatectomy.
    Paparel P; Cronin AM; Savage C; Scardino PT; Eastham JA
    Eur Urol; 2009 Feb; 55(2):404-10. PubMed ID: 18639970
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A model that predicts the probability of positive imaging in prostate cancer cases with biochemical failure after initial definitive local therapy.
    Choueiri TK; Dreicer R; Paciorek A; Carroll PR; Konety B
    J Urol; 2008 Mar; 179(3):906-10; discussion 910. PubMed ID: 18207194
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Timing of androgen deprivation therapy and its impact on survival after radical prostatectomy: a matched cohort study.
    Siddiqui SA; Boorjian SA; Inman B; Bagniewski S; Bergstralh EJ; Blute ML
    J Urol; 2008 May; 179(5):1830-7; discussion 1837. PubMed ID: 18353378
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Subclassification of clinical stage T1 prostate cancer: impact on biochemical recurrence following radical prostatectomy.
    Magheli A; Rais-Bahrami S; Carter HB; Peck HJ; Epstein JI; Gonzalgo ML
    J Urol; 2007 Oct; 178(4 Pt 1):1277-80; discussion 1280-1. PubMed ID: 17698121
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment of men with rising prostate-specific antigen levels following radical prostatectomy.
    Tzou K; Tan WW; Buskirk S
    Expert Rev Anticancer Ther; 2011 Jan; 11(1):125-36. PubMed ID: 21166517
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Is routine digital rectal examination required for the followup of prostate cancer?
    Warren KS; McFarlane JP
    J Urol; 2007 Jul; 178(1):115-9. PubMed ID: 17499293
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Salvage radical prostatectomy for recurrent prostate cancer after radiation therapy.
    Leonardo C; Simone G; Papalia R; Franco G; Guaglianone S; Gallucci M
    Int J Urol; 2009 Jun; 16(6):584-6. PubMed ID: 19453762
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prostate specific antigen nadir determined using ultra-sensitive prostate specific antigen as a predictor of biochemical progression after radical prostatectomy in Japanese males.
    Kinoshita H; Kamoto T; Nishiyama H; Nakamura E; Matsuda T; Ogawa O
    Int J Urol; 2007 Oct; 14(10):930-4; discussion 934. PubMed ID: 17880291
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tumor volume does not predict for biochemical recurrence after radical prostatectomy in patients with surgical Gleason score 6 or less prostate cancer.
    Merrill MM; Lane BR; Reuther AM; Zhou M; Magi-Galluzzi C; Klein EA
    Urology; 2007 Aug; 70(2):294-8. PubMed ID: 17826492
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Importance of tumor location in patients with high preoperative prostate specific antigen levels (greater than 20 ng/ml) treated with radical prostatectomy.
    Magheli A; Rais-Bahrami S; Peck HJ; Walsh PC; Epstein JI; Trock BJ; Gonzalgo ML
    J Urol; 2007 Oct; 178(4 Pt 1):1311-5. PubMed ID: 17698095
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.